Efungumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEfungumab
Drug Alias Name依芬古单抗efungumabum依芬谷单抗efungumabMycograb +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionHeat shock protein HSP90 inhibitors
TargetsHeat shock protein HSP90
Therapy Area/IndicationsBreast NeoplasmsMeningitis, CryptococcalCandidiasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandSerbia +[5] 
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaN/A
Originator CompaniesNeutec Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeutec Pharma LtdNovartis Pharma AgNeutec Pharma
Active IndicationsN/A
Inactive IndicationsBreast NeoplasmsMeningitis, CryptococcalCandidiasis

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG